The purpose of this study is to compare how well odronextamab combined with chemotherapy works compared to rituximab combined with chemotherapy in people who have not received treatment for their follicular lymphoma before. The study will also look at whether odronextamab is safe and what side effects it may cause. The study is divided into two parts. Part 1 will test the safety of odronextamab when given with chemotherapy and will help determine the best dose to use. Part 2 will compare the two treatment combinations to see which one works better at helping patients achieve a complete response, which means that signs of cancer can no longer be detected.

During the study, participants will receive their assigned treatment through an infusion into a vein or by mouth, depending on the specific medicine. The study will monitor participants through various tests including imaging scans such as computed tomography or magnetic resonance imaging to measure how the disease responds to treatment. Participants will also be asked to complete questionnaires about their quality of life and any symptoms they experience. The study will track how long the cancer stays under control, whether it comes back, and how long participants live. Blood samples will be taken to measure drug levels in the body and to check if the body develops any immune response to the treatment.

The study will monitor patients who continue taking tazemetostat either alone or in combination with other approved or experimental medications. During the study, researchers will track any side effects that may occur and how well patients tolerate the medication over an extended period. The medication will be provided according to each patient’s previous treatment plan.

Participants will be monitored for various health measures, including their blood cell counts, kidney function, and liver function. The study will also track how long patients survive while receiving the treatment. This is an open-label study, which means all participants will receive the active medication, and there is no use of a placebo.

The purpose of the study is to evaluate how well Odronextamab works in shrinking tumors and to assess its safety in patients. The study includes several subtypes of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will collect information on how the cancer responds to Odronextamab and any changes in the patients’ health. This information will help determine the effectiveness of the treatment and its potential as a new option for patients with B-cell non-Hodgkin lymphoma. The study aims to provide valuable insights into the treatment of this type of cancer and improve future care for patients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The purpose of the study is to explore how effective Mosunetuzumab is when used as a second-line treatment for patients whose follicular lymphoma has returned or worsened within 24 months after their first treatment. Participants in the study will receive Mosunetuzumab over a period of time, and their health will be monitored to see how the cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Mosunetuzumab.

The study will follow participants for a period of up to four years to observe their progression-free survival, which means the length of time during and after treatment that the cancer does not get worse. Other aspects being studied include the overall response rate to the treatment, the duration of response, and the safety and tolerability of Mosunetuzumab. The trial aims to gather important information that could help improve treatment options for people with follicular lymphoma in the future.

The purpose of the study is to see how well these treatments work in controlling the cancer. Participants will be randomly assigned to receive one of the treatment combinations. Some participants will receive zanubrutinib with obinutuzumab, while others will receive lenalidomide with rituximab. The study will also look at how long the treatments can keep the cancer from getting worse and how they affect the overall health and quality of life of the participants. The study will take place over several months, with regular check-ups and assessments to monitor the participants’ health and the progress of the treatment.

Throughout the study, participants will undergo various tests, including imaging tests like MRI or CT scans, to measure the size of the cancer and see how it responds to the treatment. The study aims to provide valuable information on which treatment combination is more effective for patients with relapsed or refractory follicular or marginal zone lymphoma. This information could help improve future treatment options for these types of cancer.

Participants in the study will receive either tisagenlecleucel or one of the standard treatments, which may include medications like rituximab, cyclophosphamide monohydrate, doxorubicin hydrochloride, vincristine sulfate, prednisone, prednisolone, fludarabine phosphate, lenalidomide, bendamustine hydrochloride, or tocilizumab. Some participants may receive a placebo. The purpose of the study is to determine if tisagenlecleucel can improve the time patients live without their disease getting worse, which is known as progression-free survival.

The study will involve regular visits to the clinic for treatment and monitoring. Participants will undergo various tests and assessments to track their health and the progress of their disease. The trial will last for several years, with the aim of gathering comprehensive data on the safety and effectiveness of tisagenlecleucel compared to standard treatments. This information will help determine the best treatment options for patients with relapsed or refractory follicular lymphoma.